Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil

Autores na Equipe: Fernanda D&#8217;Athayde Rodrigues, Ivan Zimmermann
Periódico/Edição: Value in Health Regional Issues
Ano: 2024
Link para acesso: https://pubmed.ncbi.nlm.nih.gov/38181723/

Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil